A5076129620- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Protein Kinase Regulation and GTPase Signaling
- Immunotherapy and Immune Responses
- Multiple Myeloma Research and Treatments
- Cytokine Signaling Pathways and Interactions
- Animal Genetics and Reproduction
- Lymphoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Galectins and Cancer Biology
- Hepatitis B Virus Studies
- Peripheral Neuropathies and Disorders
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Drug Transport and Resistance Mechanisms
- Genomics and Rare Diseases
- Multiple Sclerosis Research Studies
- Viral-associated cancers and disorders
- Insect Resistance and Genetics
- Angiogenesis and VEGF in Cancer
- NF-κB Signaling Pathways
AbbVie (United States)
2017-2025
NHS Greater Glasgow and Clyde
2015-2020
University of Glasgow
2013-2015
Blood Cancer UK
2013-2015
Beatson West of Scotland Cancer Centre
2015
St. Joseph's Hospital and Medical Center
2009
PDL BioPharma (United States)
2006-2008
Wellcome Sanger Institute
1998-2005
Australian Centre for Disease Preparedness
1995
Commonwealth Scientific and Industrial Research Organisation
1995
Abstract Purpose: We generated a humanized antibody, HuLuc63, which specifically targets CS1 (CCND3 subset 1, CRACC, and SLAMF7), cell surface glycoprotein not previously associated with multiple myeloma. To explore the therapeutic potential of HuLuc63 in myeloma, we examined detail expression profile CS1, binding properties to normal malignant cells, antimyeloma activity preclinical models. Experimental Design: was analyzed by gene profiling immunohistochemistry myeloma samples numerous...
Abstract Costimulatory receptors such as glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR) play key roles in regulating the effector functions of T cells. In human clinical trials, however, GITR agonist antibodies have shown limited therapeutic effect, which may be due to suboptimal receptor clustering-mediated signaling. To overcome this potential limitation, a rational engineering approach is needed optimize agonist-based immunotherapies. Here we show bispecific...
Abstract Cytokine therapies have been shown to be efficacious but are largely limited in their utility due toxicity issues. Systemic IL-15 is not well tolerated humans as it induces CRS patients with melanoma and renal cancer. To address systemic toxicity, we designed a nectin-4 targeted conditional immuno-cytokine (IC) that limits bioactivity targets the tumor microenvironment (TME). The hypothesis will enhance anti-tumor efficacy supported by data demonstrates ∼ 80 % complete response rate...
The C-terminal catalytic domain (residues 704-1047) of the human ras GTPase-activating protein (GAP) has been engineered so as to incorporate tripeptide, Glu-Glu-Phe, at its C terminus. This motif is recognized by commercially available YL1/2 monoclonal antibody alpha-tubulin and previously used for immunoaffinity purification HIV enzymes contain this epitope (Stammers, D. K., Tisdale, M., Court, S., Parmar, V., Bradley, C., Ross, C. K. (1991) FEBS Lett. 283, 298-302). GAP (GAP-344) was...
Normal and mutated cDNAs of Ha-ras have each been cloned into a standard (pAc373) novel (p36C) baculovirus transfer vector introduced via homologous recombination the genome Autographa californica nuclear polyhedrosis virus immediately downstream polyhedrin promoter. Spodoptera frugiperda cells infected with recombinant containing normal gene express very high levels ras p21 protein (approximately 20% total cell protein), whereas mutant was expressed at considerably lower levels. Molecular...
Kirsten-ras is the oncogene most frequently activated in human tumors. Studies of its biological function have been limited by nonavailability significant amounts major protein product, (4B) p21. When expressed Escherichia coli K12, recombinant was rapidly cleaved upon cell lysis lysine-rich C terminus region, probably ompT protease. However, soluble full-length obtained when gene an E. strain lacking gene, and also a baculovirus/insect expression system. Additionally, system produced about...
A multi-step procedure has been developed for the purification of [acyl-carrier-protein] acetyltransferase from Escherichia coli, which allows production small amounts homogeneous enzyme. The subunit Mr was estimated to be 29,000 and native 61,000, suggesting a homodimeric structure. catalytic properties enzyme are consistent with Bi Ping Pong mechanism existence an acetyl-enzyme intermediate in cycle. inhibited by N-ethylmaleimide more slowly iodoacetamide reactions protected substrate,...
Background Although the concept that an initial course of immune-suppression facilitates subsequent immune-modulation (such as Th1 to Th2 deviation) is attractive for several autoimmune diseases, such a mechanism serial-combination therapy has never been formally demonstrated. Recently, brief mitoxantrone induction-chemotherapy followed by with glatiramer acetate (GA) was significantly more effective at reducing multiple sclerosis disease activity than GA alone. Objective To examine whether...
In a Phase 1 clinical study, treatment with enavatuzumab, humanized monoclonal antibody to TweakR, resulted in liver toxicity subset of patients. The objective this current study was evaluate the ability preclinical studies predict humans. Enavatuzumab evaluated cynomolgus monkeys, where serum enzyme and cytokine levels were measured histopathology performed. TweakR expression by immunohistochemistry healthy human tissues from cancer also vitro for its impact on hepatocytes when cultured...